AACR: Akeso’s Cadonilimab Shows 1L Potential In Adenocarcinoma

Promising Interim Phase III Data

 
• By Dexter Jie Yan
  
gastric cancer
positive results help Akeso's cadonilimab position as standard 1L therapy for G/GEJ adenocarcinoma • Source: Shutterstock

More from China

More from Focus On Asia